Author Archives: Guest Blogger

The Sovaldi Case: Is American Biotech History About to Repeat Itself?

Recent Congressional investigations over the pricing scheme of Gilead’s much-heralded hepatitis C drug Sovaldi – and a decline in stocks across the biotech sector – rings a familiar bell, writes Tom Norton. Twenty years ago in May, US Senator Joe Lieberman carefully questioned biotech CEO Harry Penner of then Neurogen Corporation about why his company’s […]
Posted in Biotech, healthcare, leadership, Market Access, pricing, R&D, Sales, Strategy | Tagged , , , , , , , , , | 1 Comment

Is Gender a Drug Safety Issue in the Era of Personalized Medicine?

By Lisa Henderson, Applied Clinical Trials. In January 2013, FDA told manufacturers to lower the dose of zolpidem, the insomnia treatment, for women, and suggested a 10 mg to 5 mg for immediate-release products (Ambien, Edluar, and Zolpimist) and from 12.5 mg to 6.25 mg for extended-release products (Ambien CR). That was based on evidence […]
Posted in FDA, Gene therapy, Regulatory, Safety | Tagged , , , , | Leave a comment

Chats Not Charts: Three Steps to Pharma Post-Marketing

by Andrew Spong (originally published on stwem.com) The air of despondency that is descending over the pharmaceutical industry’s use of social media is perverse. It has nothing to do with a putative (and also fictive) absence of interest on the patient’s part in connecting with the pharmaceutical industry. It has everything to do with the […]
Posted in Advertising, E-Media, Guest Blog, leadership, Marketing, Patient Communication, patient education, social media, Strategy | Leave a comment

Closed-Loop Marketing: What Comes Next?

By Morten Hjemlsoe. One of the questions I’m increasingly being asked at conferences is, “What’s next after CLM?” That’s actually rather nice to hear. To me, the question is like those delightful birds, the swallows, whose appearance announces that spring is on its way: it signifies that we’re ready for things to change.
Posted in E-Media, Guest Blog, Marketing, multimedia, Technology | Tagged , , , , , | Leave a comment

Pharma Marketers: Avoid the Tactical Scrum

by Al Topin With the introduction of every new technology, tactic, or gimmick comes what I call a tactical scrum. It’s like watching young kids play their first game of T-ball or soccer. No matter how much instruction the coach gives on field position or game play, the second that ball is hit or kicked, […]
Posted in Advertising, Agency Insight, E-Media, Guest Blog, Marketing, People, Sales, social media, Strategy, Technology | Tagged , , , | Leave a comment
  • Categories

  • Meta